Over the course of the projection period, it is anticipated that a rise in the ophthalmic drug shortage will propel market expansion. For instance, the Department of Health and Human Services' 2019 report states that the dosage type most frequently provided by 503B certified facilities was injectable; consequently, in 2018, over 53 U.S. outsourcing facilities provided injectable compounded medications. The remaining sterile liquids, solids, semi-solids, and non-injectable dosage forms came next.
The market for Ophthalmic Compounding Pharmacies in the United States is anticipated to reach US$ 219.2 million in 2021 and grow at a CAGR of 5.0% from 2021 to 2028.
Leading Companies in the Us Ophthalmic Compounding Pharmacies Industry:
Fagron Sterile Services US:
Pharmaceutical preparations are the primary business of Wichita, Kansas-based private corporation Fagron Compounding Services. created in 2014. office in the U.S. The top company in the world for pharmaceutical compounding, Fagron, has purchased a 503B outsourcing plant in Boston from Fresenius Kabi.
Nora Apothecary:
Owner of a pharmaceutical business that aims to offer inexpensive, high-quality medicinal items. The business specialises in producing and distributing generic and specialised medications all over the nation. Founded in 2017. Headquarters in Canada.
Lifecare Pharmacy:
A group of three specialised pharmacies with locations in Texas's Laurel Heights, Pavilion, and Empire. United States headquarters. Avita's local presence will double with the acquisition of Lifecare Pharmacy's Laurel Heights, Pavilion, and Empire sites.
